Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function

Sponsor
Sun Yat-sen University
Study ID
NCT01790308
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • CSII — DRUG
    continuous subcutaneous insulin infusion for 2\~4 weeks
  • Liraglutide — DRUG
    CSII for 2\~4 weeks combined with Liraglutide 0.6mg/d for 1 month and 1.2mg/d for next 2 months

Study Details

The purpose of this study is to investigate and evaluate the effects of liraglutide combined with short-term continuous subcutaneous insulin infusion(CSII) on long-term glycemic control and β-cell function in newly diagnosed type 2 diabetic patients.

Key Dates

Start date
Feb 28, 2013
Status verified
Feb 2013
Primary completion
Dec 31, 2014
Completion
Dec 31, 2015

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: CSII
    continuous subcutaneous insulin infusion for 2-4 weeks
  • Active Comparator: Liraglutide
    continuous subcutaneous insulin infusion for 2-4 weeks combined with combined with Liraglutide 0.6mg/d for 2-4 weeks and 1.2mg/d for next 9 weeks

Primary Outcome Measure

the percentage of the patients who maintain glucose control 1 year after short intensive therapy [ Time Frame: 1 year ]

Related Studies